Novagali Pharma SA

Oxeia Biopharmaceuticals Inc. has appointed Michael Wyand CEO and to its board of directors. Most recently, Wyand was president and chief operating officer of Epirus Biopharmaceuticals Inc. a

Idenix Pharmaceuticals Inc. has been quite busy of late, on the fundraising front and elsewhere. A clinical-stage biotech with a market cap of nearly $900 million and no marketed products, the virol

The half-year data are in. Public biopharma firms raised $3.14 billion in secondary offerings through the end of June. According to Elsevier’s Strategic Transactions database, that surpasses the f

Four years after closing the BioDiscovery 3 at €156 million, Edmond de Rothschild Investment Partners is now on the road raising a €200 million fourth fund to invest innovative European life sciences